Abstract Introduction Peyronie’s disease (PD) is a chronic fibrotic condition of the tunica albuginea, leading to penile curvature and sexual dysfunction. Platelet-rich plasma (PRP) has recently gained attention as a regenerative approach with potential anti-fibrotic and disease-modifying effects. However, clinical evidence in men with stable PD remains limited. Objective To evaluate the safety and clinical efficacy of intralesional PRP injections in men with chronic, stable PD. Methods A retrospective cohort study was conducted involving men with chronic PD who received three weekly intralesional PRP injections between April 2022 and April 2025. Eligible participants presented with stable curvature (≥6 months) and no prior PD-specific treatments. The primary endpoint was change in penile curvature 4 weeks after the final injection. Secondary endpoints included changes in plaque thickness (ultrasound), erectile function assessed by the International Index of Erectile Function-5 (IIEF-5), and treatment safety according to the Clavien–Dindo classification. Results A total of 36 men (mean age 61.2 ± 10.4 years) completed the treatment protocol. Mean penile curvature decreased from 30.5 ± 7.3° to 24.2 ± 8.3° (Δ = −6.3°, 95% CI −7.7 to −5.3; p 0.001), with 25% of patients achieving a ≥10° reduction. Plaque thickness decreased from 3.25 ± 0.69 mm to 2.91 ± 0.76 mm (Δ = −0.34 mm; p 0.001). Erectile function scores showed a modest, non-significant improvement (mean Δ = +1.1; p = 0.142). Adverse events were mild and transient, including localized pain (5.6%) and minor hematoma (2.8%), with no major complications reported. Conclusions Intralesional PRP injections were safe and associated with modest but statistically significant reductions in penile curvature and plaque thickness in men with chronic PD. Although clinically meaningful improvement was observed in a subset of patients, the overall efficacy remains limited. These findings suggest that PRP should be considered experimental pending validation in larger, prospective, randomized controlled trials with standardized preparation and longer follow-up. Disclosure No
Manfredi et al. (Mon,) studied this question.